RecruitingPhase 2NCT06202066

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Roswell Park Cancer Institute
Principal Investigator
Jasmeet Kaur, MD
Roswell Park Cancer Institute
Intervention
Biospecimen Collection(procedure)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06202066 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials